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1. Introduction 
Colorectal cancer is the second-leading cause of cancer-related deaths in Europe and the 
United States (Parkin DM, 2001). Although the primary therapy of CRC is surgical, the 
elucidation of different novel prognostic markers may prove to serve as future therapeutic 
options and contribute to the overall understanding of this cancer entity, as well as to 
improver disease outcome. Inflammation has been known to be a key factor of development 
and progression of cancer, and this is particularly notable in colorectal. At the cellular level, 
the colonic epithelium is exposed to a range of toxic and pathogenic challenges, including 
the balance between intestinal microflora. In turn, a shift can result in a change in immune 
response, leading to the induction of inflammation. Interactions between tumor and 
immune cells at the site of inflammation either enhance or inhibit cancer progression. The 
epidemiological data available are very impressive and show a clear association between 
chronic inflammatory conditions and subsequent malignant transformation in the inflamed 
tissue (Macarthur et al., 2004). New evidence suggests that up to 25% of all cancers are due 
to chronic infection or other types of chronic inflammation (Hussain SP, et al., 2007). 
Inflammation is mediated by an array of cytokines, which are synthesized by activated 
immune cells and exert their biological activities upon binding to specific receptors and 
activate the NF-κB transcription factor signal pathway in the epithelial cells. The ubiquitous 
transcription factor family NF-κB is a central regulator of the transcriptional activation of a 
number of genes involved in cell adhesion, immune and proinflammatory responses, 
apoptosis, differentiation, and growth. Induction of these genes in intestinal epithelial cells 
by activated NF-κB profoundly influences mucosal inflammation and repair (Jobin and 
Sartor, 2000). 
There is strong evidence to suggest that cytokines are involved in the control of cancer 
development and also promote tumorigenesis, invasion, propagation, and metastasis of 
tumors, and that they may be relevant for gastrointestinal tumors. More recently, the 
molecular mechanism whereby the inflammation regulates the antitumor immune 
responses has been elucidated. In many tumors, signal transducers and activator of 
transcription (STAT)3 are activated, and thereby antitumor immune surveillance is 
suppressed (H. Yu and R. Jove, 2004).  
In general the genes that encode cytokines involved in regulation of inflammatory 
conditions are genetically polymorphic and different genotypes are responsible for level of 
protein expression. 
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Genetic polymorphisms have emerged in recent years as important determinants of disease 
susceptibility and severity. Polymorphisms are naturally occurring DNA sequence 
variations, which differ from gene mutations in that they occur in the normal healthy 
population and have a frequency of at least 1%. Approximately 90% of DNA 
polymorphisms are single nucleotide polymorphisms (SNPs) due to single base 
substitutions. Others include insertion/deletion polymorphisms, minisatellite and 
microsatellite polymorphisms. Although most polymorphisms are functionally neutral, 
some have effects on regulation of gene expression or on the function of the coded protein. 
These functional polymorphisms, despite being of low penetrance, could contribute to the 
differences between individuals in susceptibility to and severity of disease. Many studies 
have examined the relationship between certain cytokine gene polymorphism, cytokine 
gene expression in vitro, and the susceptibility to and clinical severity of diseases (Bidwell et 
al., 1999; Hollegaard and Bidwell, 2006). SNPs are the most common sources of human 
genetic variation, and they may contribute to an individual’s susceptibility to cancer. 
Cytokine gene polymorphisms have emerged in recent years as important determinants of 
susceptibility and severity of colorectal cancer. Cytokine polymorphisms directly influence 
interindividual variation in the magnitude of cytokine response, and this clearly contributes 
to an individual's ultimate clinical outcome. Dysregulation of cytokine production strongly 
influenced both tumor progression and host anti-tumor immunity. Cytokines secreted by 
activated immune and inflammatory cells can either promote tumor cell survival and 
growth or exert antitumor effects. In addition, some tumor cells may evade the immune 
system by secreting cytokines which may induce regulatory cells particularly the 
immunosuppressive CD4+CD25+ FoxP3+ T regulatory cells. In this chapter the 
polymorphisms of selected candidate genes for susceptibility to and/or severity of CRC are 
reviewed. Special attention is paid to studies concerning the genes of inflammatory related 
cytokines. 
2. Cytokine gene polymorphisms of proinflammatory cytokines: IL-1; TNF- 
and IL-6 
The most compelling evidence for the role of inflammation in CRC comes from studies 
showing that proinflammatory cytokine gene polymorphisms increase the risk of cancer and 
its precursors.  
IL-1ǃ is a prominent proinflammatory cytokine, which together with tumor necrosis factor-
 (TNF-) serve as primary initiators of the complex inflammatory response and they are 
classical activators of NFkB signaling pathway. IL-1 and TNF- genes have a number of 
functional polymorphisms. The IL-1B-31T/C and TNF-A-308G/A SNPs have been shown to 
be functionally significant with the C allele of IL-1B-31T/C and A allele of TNF-A-308G/A 
being associated with increased production of their respective cytokines (Hwang et al., 2002; 
Abraham and Kroeger, 1999). IL-1 gene cluster polymorphisms suspected of enhancing 
production of IL-1 have been shown to be relevant in the development of H. pylori-
associated gastric adenocarcinoma. A study published in Nature showed for the first time 
that polymorphisms in interleukin-1B (IL-1B) were associated with gastric cancer risk (El 
Omar et al, 2000). Two of these polymorphisms are in near-complete linkage disequilibrium 
and one is a TATA-box polymorphism that markedly affects DNA–protein interactions in 
vitro. These linked IL-1B single nucleotide polymorphisms that increase IL-1ǃ expression 
www.intechopen.com
 
Cytokine Gene Polymorphisms in Colorectal Cancer 
 
61 
(−511 C>T and −31 T>C) were associated with a 2- to 3-fold increased risk of gastric cancer. 
Heterozygosity at the IL1B −31T/C locus has also been associated with colorectal adenoma, 
a precursor of colorectal cancer (Gunter et al., 2006). However, Macarthur et al., 2005 did not 
reveal significant associations between the cytokine polymorphisms of IL-1B-31T/C and risk 
of colorectal cancer. In the same directions are results obtained by Ito et al., 2007 for the 
same SNP in IL-1B. Simultaneously they found that IL-1B-511 heterozygotes and T carriers 
had a significantly low risk for gastric and colorectal carcinoma in the Japanese population. 
The TNF cytokines are well known for their cytotoxic and antitumor activity. TNF- is a 
proinflammatory cytokine secreted mainly by activated monocytes/ macrophages. TNF- 
mediates the early inflammatory response and regulates the production of other cytokines, 
including IL-1 and IL-6. TNF- gene is transcriptionally silent in unstimulated monocytes 
and is rapidly transcribed in response to a variety of signals, such as bacterial endotoxin 
(LPS) and other stimuli. The signaling cascades leading to TNF- production bifurcates to 
control both transcription of TNF- gene and translation of TNF- m RNA (Swantek et al., 
1997). Transcriptional control of the TNF- gene is mediated primarily by NF-kB binding 
sites present within the TNF- gene promoter (Sweet and Hume, 1996; Yao et al., 1997). One 
microsatellite polymorphism in the vicinity of the TNF-ǂ gene (TNF-A) has 14 different 
alleles (a1–a14). The a6 allele was associated with lower TNF-ǂ secretion from activated 
monocytes (Pociot et al., 1993). For this TNF-ǂ polymorphism, one allele was associated 
with an increased risk (a2 allele) and two other TNF-A alleles with decreased risks (a5 and 
a13 allele) of CRC (Gallagher, G et al., 1997; De Jong et al., 2002).  
Among the other investigated polymorphisms of the TNF-ǂ gene, the promoter -308G/A 
SNP was intensively studied. The presence of TNF-ǂ -308A allele involved in gene 
transcription is associated with higher levels of TNF-ǂ. Park et al., investigated TNF-A and 
Ncol RFLP of TNF-B genes and the risk of CRC (Park et al., 1998). The first intron of TNFB 
and the -308 promoter region of TNFA SNP polymorphisms were determined in 136 
colorectal cancer patients and 325 healthy controls in an Asian population. Their results 
indicated that homozygous TNF-B*1/TNF-B*1 genotypes showed an increased risk for 
colorectal cancer, although no association in tumor susceptibility was found for the −308 
G/A polymorphism of the TNF-ǂ gene when comparing colorectal cancer patients and 
healthy controls. Landi et al., 2003 found a trend of reduced risk for CRC in TNF -308A 
allele carriers, but Theodoropoulos et al., 2006 found no effect of this SNP and the risk of 
CRC in Greek population.  
For another SNP in TNF-ǂ gene promoter, the −238 G > A site, has been reported that the A 
allele decreases the risk of developing colorectal cancer (Jang et al., 2001). Up to now, 
however, most studies have focused more on other cancer entities, such as melanoma and 
breast cancer, than on colorectal cancer. 
The TNF-ǂ pro-cancerous effect has recently been established. It’s binding to specific 
receptors sets up signal transduction pathways, leading to cell apoptosis and gene 
regulation, via the MAPKinase and NF-kB pathways (Waterston A, and Bower, 2004).  
Interleukin-6 (IL-6) is a pleiotropic cytokine that is participates in physiological and 
pathological processes for a variety of human malignancies including colorectal cancer. In 
particular, a preoperative IL-6 level is correlated with tumor stage, survival rate, and liver 
metastasis in CRC (Nakagoe et al., 2003). A significant association between serum IL-6 level 
and staging of the tumor (P<0.001), tumoral tissue IL-6 level (r=0.95, P<0.001) in the patients 
was founded (Esfandi F et al, 2006). IL-6 amount of the serum and tumoral tissue in the 
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patients with colorectal cancer correlate significantly with the staging of the tumor and with 
each other. It has been demonstrated that IL-6 acts as a colorectal growth factor and as an 
autocrine growth factor for colorectal cancer cells (Chung and Chang, 2003).  
A common G/C polymorphism located within the IL-6 gene promoter (chromosome 7p21) 
at position 174 bp, upstream from the start site of transcription (−174 G/C locus), has been 
reported (Fishman D et al, 1998). This promoter SNP affects the transcription of the gene, 
and altering the final levels of IL-6 released (Terry et al., 2000, Bonafe et al., 2001). The G 
allele increases IL-6 expression, both in stimulated and non stimulated conditions, the 
highest IL-6 levels being found in subjects homozygous for the G allele. In the same line are 
data of Belluco at al., 2003 for increased serum levels of IL-6 in colorectal cancer patients 
with genotype GG, regardless of the tumor stage, grade and location. Moreover, they also 
found a close correlation between high levels of circulating IL-6 and the presence of hepatic 
metastasis. The association between IL-6 serum level and CRC hepatic metastasis may 
depend on IL-6 properties to up-regulating the expression of adhesion receptors on 
endothelial cells and inducing the production of growth factors, such as hepatocyte growth 
factor and vascular endothelial growth factor, both of which may stimulate tumor 
metastasis. IL-6 promoter activation involves synergism between the transcription factors 
NF-IL-6 and NF-κB (Huang et al, 2000), and this may explain increased IL-6 serum levels in 
the CRC patients with hepatic metastasis. The first report, for investigation the promoter 
polymorphism in IL-6 gene with sporadic colorectal cancer risk has been the study of Landi 
et al., 2003. They found that the allele IL6 −174C is associated with increased risk of CRC. 
This association was seen both under a codominant model as well as when genotypes were 
grouped for both cancer of the colon and cancer of the rectum. A possible explanation of this 
effect is that the -174C allele could cause increased inflammation for colorectal cells in 
response to activated neutrophils (Nusrat et al., 2001). Slattery and colleagues reported that 
the GG genotype of the −174 G/C IL-6 polymorphism was associated with a significantly 
reduced risk of colon, but not rectal, cancers (Slattery et al., 2007). The IL6 −174C allele’s role 
in CRC risk could not be replicated in the studies of others collectives (Theodopoulos et al., 
2006; Cacev et al., 2010).  
A possible cause for the conflicts and mismatches, like those observed here and the earlier 
study in allele and genotype distributions, may be the differences in racial or ethnical 
backgrounds. Duch et al. analyzed 52 patients with multiple myeloma and found that the G 
allele frequency was higher in the Brazilian population than in the European population 
(Duch C et al., 2007). Nowadays Yeh et al. observations on the allele and genotype 
distribution of the IL-6 −174 G/C polymorphism demonstrated that there are low 
frequencies of the G allele and GG genotype in the Taiwanese CRC population compared to 
the Western counterpart (Yeh et al., 2009).  
Experimental data suggest that IL-6 plays an important role not only in developed but also 
in the progression of metastasis from colorectal cancer. In CRC patients, high expression of 
IL-6 has been correlated with poor survival and IL-6 -174 genotype CC was also significantly 
associated with shorter survival time when compared with the heterozygous genotype CG 
(Chung YC et al., 2006; Wilkening et al., 2008). Also, Belluco and colleagues analyzed 62 
CRC patients and observed that patients with the C allele had lower serum IL-6 levels than 
those without the C allele, particularly in the presence of hepatic metastasis (Belluco C et al., 
2003).  
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Specifically, IL-6/IL-6R complexes initiate homodimerization of gp 130, activate a 
cytoplasmic tyrosine kinase, and trigger signaling cascades through the JAK/STAT, 
Ras/MAPK and PI3-K/AKT pathways (Su et al., 2005; Chung YC et al., 2006). It has been 
shown that activation of signal transducers and activators of transcription 3 (STAT3) a 
member of a family of six different transcription factors is constitutively active in CRC cells 
(Corvinus et al., 2005). Ones of main activators of these signal transducers are 
proinflamatory cytokines such as IL-6, TNF- and growth factors. STAT3 activity in CRC 
cells triggered through interleukins was found to be abundant in dedifferentiated cancer 
cells and infiltrating lymphocytes of CRC samples. These actions regulate inflammatory 
reactions, immune responses, and several other pathophysiological processes of malignancy 
including cell growth and survival, differentiation, cell mobility and angiogenesis. Thus, the 
presence of proinflammatory cytokine polymorphisms in colorectal cancer development 
remains a pertinent question and one that we are not aware of other investigators having 
considered.  
3. Cytokine gene polymorphisms of antiinflamatory cytokines: TGF-  
and IL-10 
Anti-inflammatory cytokines play an important role in downregulation of inflammation and 
the prevention of neoplastic disorders. Genetic variations of anti-inflammatory cytokines are 
assumed to influence such responses. Typical anti-inflamatory cytokines (TGF-beta and IL-
10) with immunosuppressive effect are secreted mainly from T regulatory cells (Tregs). 
Transforming growth factor-beta (TGF- or TGFB) is an immunoregulatory cytokine that 
plays an important role in tumor immune response within the gastrointestinal tract and this 
is shown in TGFB gene knockout mice, which proceed to develop uncontrolled 
inflammatory response and early death (Kulkarni et al., 1993). In mammalian cells, there are 
three isoforms described TGFB1, TGFB2, and TGFB3. Among them TGFB1 is the most 
abundant subtype. 
TGF ǃ1 is involved in many critical cellular processes, including cell growth, extracellular 
matrix formation, cell motility, angiogenesis, hematopoiesis, apoptosis, and immune 
function (Moustakas et al., 2002; Schuster & Krieglstein, 2002). All immune cell lineages, 
including B, T and dendritic cells as well as macrophages, secrete TGF-, which negatively 
regulates their proliferation, differentiation and activation by other cytokines. 
The TGF- signaling pathway plays an important role in controlling cell proliferation and 
differentiation involved in colorectal carcinogenesis. Binding of cytokine to the TGF- 
receptor complex leads to phosphorylation of Smad proteins and triggers Smads 
intracellular signaling mediators to modulate gene transcription, mainly by transcription 
factor Sp1. Xu and Pasche, 2007 shown that TGF- signaling alterations have been 
implicated in susceptibility to colorectal cancer. 
In normal intestinal epithelium TGF-ǃ1 acts as a growth inhibitor, however loss of TGF-ǃ1 -
mediated growth restraint has been shown to be associated with the transformation of 
colorectal adenoma to cancer. In addition, there is evidence that excess production and/or 
activation of TGF- by cancer cells can contributed to the tumor progression by paracrine 
mechanisms involving neoangiogenesis, production of stroma and proteases, and 
subversion of immune surveillance mechanisms in tumor hosts (Muraoka-Cook et al., 2005). 
Moreover, TGF- is the most frequently up-regulated in tumor cells (Elliott and Blobe, 2005). 
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TGF-ǃ1 is also a potent effector within the tumor microenvironment. It exerts a 
predominantly immunosuppressive effect on CD8+ cytotoxic T-lymphocytes and has been 
shown an active player in tumor immune evasion (Li et al., 2006). Friedman et al. reported 
that high levels of transforming growth factor ǃ1 correlate with disease progression in 
human colon cancer (Friedman et al. 1995). In light of these finding TGF-ǃ1 gene is a 
functional candidate gene for genetic predisposition in CRC.  
The TGF-1 gene is located on chromosome 19 and several SNPs were described in 
promoter region, in the non-translated region (introns), in the coding region (exons), and in 
the 3’-UTR region of the gene (Watanabe et al., 2002). Certain inherited variants in the 
promoter region of the TGF- gene (-800G/A and -509C/T) have been associated with 
higher cytokine circulating concentrations. The -800G/A SNP is located in a consensus 
cyclic AMP response element binding protein (CREB) half site and may cause reduced 
affinity for CREB transcription factors whose binding is important for transcription control 
(Grainger D et al., 1999). The -509C/T is located within a YY1 consensus binding site and -
509T allele has been associated with increased TGF-1 plasma level (Grainger D et al., 1999) 
and reduced T-cell proliferation (Meng et al., 2005). Moreover these two SNPs of the TGF- 
gene are in linkage disequilibrium. The 509 C/T polymorphism has been implicated in both 
colorectal adenoma and cancer risk. However, published data remains conflicting. 
In the study of Macarthur et al., 2005 no association was found between -509C/T SNP in 
TGF-1 promoter and colorectal cancer. Authors investigated also association between 
cytokine polymorphisms of IL-1, IL-10 and TNF-ǂ genes in a population based case-control 
study of 264 CRC patients and 408 controls in the Northeast of Scotland and analyzed their 
interaction with regular aspirin use. The beneficial association between nonsteroidal anti-
inflammatory drugs use, such as aspirin and decreased risk of colorectal cancer provided 
further evidence to suggest a role for chronic inflammation in the pathogenesis of sporadic 
colorectal cancer. Whereas a statistically significant association was not found between any 
of the SNPs and CRC alone, the authors observed a significant interaction between the IL-
10-592 genotype and aspirin use. The effect of aspirin on CRC risk was limited to carriers of 
low producing A allele (AA and AC) compared with CC genotype. The authors postulated 
that individuals who are genetically prone to producing reduced levels of the anti-
inflammatory IL-10 (i.e., carriers of the variant A allele) are more likely to benefit from the 
anti-inflammatory properties of aspirin in decreasing risk of CRC development. 
Berndt et al., 2007 examined two SNPs in the promoter region of the TGFB1 (-800G/A; -
509C/T) and two in exon 1 (Leu10Pro; Arg25Pro) and one in exon 5 (Thr263Ile) in association 
with advanced colorectal adenoma in population consisted primarily of Caucasians, living in 
the USA. The Leu10Pro and Arg25Pro SNPs encoded non synonymous amino acid 
substitution located in signal peptide sequence of the TGF-ǃ1 pro-peptide.  
Dunning et al., 2003 revealed that the 10Pro variant lead to increased TGF- secretion 
compared with the 10Leu allele. Similarly, the 25Arg allele has been associated with 
increased TGF- production upon stimulation in vitro (Awad MR et al., 1998). 
Berndt et al., reported that the high TGF- produced genotypes, −509TT and 10Pro/Pro 
genotypes were associated with an increased risk of advanced colorectal adenoma 
compared with other genotypes. These increased risks, particularly for -509TT association 
were greater for the subsets of participant with multiple adenomas and those with rectal 
adenomas. Risk factors for hyperplastic and adenomatous polyps were generally similar to 
those for colorectal cancer. Another study investigated the same Leu10Pro polymorphism in 
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association with colorectal adenoma and hyperplastic polyps. In this study no association 
was found with this SNP and adenoma, but a lower risk of hyperplastic polyps was 
suggested for Pro allele carriers who were current or past smokers (Sparks et al, 2004).  
Together these studies give support to the possible role of TGFB1 in the adenoma-carcinoma 
sequence and suggest that high TGFB1 produced genotypes may modulate the risk in this 
transformation.  
To characterize association of genetic variation at the TGFB1 gene with circulating cytokine 
levels of TGF- and risk of colorectal adenoma and adenocarcinoma, Saltzman et al., 2008 
conducted two case-control studies (including 271 colorectal adenoma cases and 544 
controls, and 535 colorectal adenocarcinoma cases and 656 controls) among Japanese 
Americans, Caucasians, and Native Hawaiians in Hawaii. The authors investigated 26 SNPs, 
spanning 39.8 kb region of the TGFB1 gene, distributed in two haplotype blocks of linkage 
disequilibrium named as tagSNPs, including all previously commented SNPs. They found 
that the variant A allele for tagSNP in 3’UTR A/G (rs6957) was associated with an increased 
serum level of TGF-, and no association with promoter -509C/T and Leu10Pro 
polymorphisms was found. However, published data remains conflicting. In the recent 
study the association between -509 C/T and -800 G/A SNPs of the TGFB1 gene, and 
susceptibility to colorectal cancer in Iranian patients was investigated (Amighofran Z et al., 
2009). They found a statistically significant lower frequency of 509T allele and TT genotype 
in patients than in control subjects. At position 800, no significant differences in genotype 
distribution and allele frequencies between the patients and healthy controls were found. 
The authors concluded that the genotype distributions and allele frequencies of the TGFB1 
gene polymorphism at -509 C/T were significantly related to colorectal carcinoma in Iranian 
subjects. In the same directions are the results of Chung et al., 2007, that -509T variant allele 
reduced risk of colorectal cancer, but not adenoma in Koreans. A possible explanation for 
discrepancy in above commented results for involvement of -509 C/T SNP in colorectal 
cancer susceptibility occurs in the investigation of Fang et al., 2010. To derive a more precise 
estimation of the relationship, a meta-analysis of 994 colorectal cases and 2,335 controls from 
five published paper was performed. Overall, significantly increased colorectal cancer risks 
were found for CC versus TT in the subgroup analysis by ethnicity. Fang et al., 2010 
concluded that TGFB1 -509 C/T substitution has a role in genetic predisposition for 
developing colorectal cancer in Asians, but no significant associations were found among 
Europeans.  
Thus far, TGF-ǃ1 −509 T/C gene polymorphisms have been also relevant to Crohn’s disease 
development (Schulte et al., 2001). In the same time patients with Crohn's disease are at 
increased risk for developing colorectal cancer. Several lines of evidence implicate chronic 
inflammation in inflammatory bowel disease (ulcerative colitis and Crohn's disease) as a key 
predisposing factor to distinct subset of colorectal tumors. (Itzkowitz and Yio, 2004). 
IL-10 is an immuno-regulatory cytokine that plays a crucial role in modulating 
gastrointestinal tract inflammation (Moore et al, 2001; Lin and Karin, 2007). IL-10 is 
produced mainly by regulatory T cell and antigen presenting cells. It is pivotal in inhibiting 
inflammation and interrupting carcinogenesis. In cancer patients, the production of immune 
suppressive cytokines: IL-10 and TGF is accelerated, and IL-10-producing type I T-
regulatory (Tr1) cells are highly infiltrated in tumor microenvironment. Thus, tumor cells 
might escape from the immune surveillance. That is the way the IL-10 gene might be 
involved in genetically predisposition and severity of CRC. 
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Large interindividual differences in the IL-10 inducibility have been observed, which has 
shown to have a genetic component of over 70%. The IL-10 gene comprises 5 exons, and it 
has been mapped to chromosome 1q31-32. To date, at least 49 IL10–associated 
polymorphisms have been reported, and an even larger number of polymorphisms are 
recorded in SNP databases (Ensembl Genome Browser, 2006). Promoter polymorphisms 
have been subject to the most studies, particularly with regard to possible influences on 
gene transcription and protein production. Three SNPs at -1082(A/G), -819(C/T), -592(C/A) 
upstream from the transcription start site (D'Alfonso S et al., 1995; Turner D et al., 1997) 
have been described as well as additional two microsatellite (CA)n repeats, termed IL-10G 
and IL-10R and located at -1151 and -3978 respectively (Eskdale J and Galager G, 1995; 
Eskdale J et al., 1997). In particular, SNP at position -1082A/G of IL-10 gene was associated 
with IL-10 production alone or in haplotypes with other distal SNPs. Turner et al.,1997 have 
shown that -1082A allele is associated with lower in vitro IL-10 production by Con A-
stimulated PBMC from normal subjects. Crawley et al., 1999 have reported that GCC 
haplotype was associated with higher IL-10 level compared to ATA in whole blood cultures 
after LPS stimulation. In our studies, the functional effect of -1082 A/G polymorphism was 
demonstrated among the Bulgarian population in both healthy volunteers and in patients 
with sepsis (Stanilova et al., 2006).  
Positive associations between IL-10 genotype or haplotype and cancer susceptibility, 
progression, or both were reported (Howell and Rose-Zerilli, 2007). The IL-10-1082/-819/-
592 genotype status was associated with an increased risk for gastric cancer in Japan. The 
presence of the ATA/GCC haplotype of IL-10-1082/-819/-592 polymorphisms significantly 
increased the risk of gastric cancer development compared with presence of the ATA/ATA 
haplotype. (Sugimoto et al, 2007). The AA genotype of the -1082 A/G polymorphism in the 
interleukin-10 gene promoter was associated with lower IL-10 production in LPS, PHA or 
PWM stimulated healthy PBMC (Stanilova et al, 2006). This cytokine possess anti-
inflammatory and immunoregulatory role and it is no wonder that IL-10 play a dual role in 
tumor development and progression (Mocellin et al., 2003; Mocellin et al, 2004; Dranoff 
2004; Lin and Karin, 2007). Contradictory results are present in the literature concerning IL-
10 systemic or tissue levels and survival of cancer patients. For instance, Mocellin et al. 
found that IL-10 overexpression within the tumour microenvironment was implicated in 
cancer immune rejection. 
Although IL-10 suppression of pro-inflammatory cytokines synthesis favors its anti-tumor 
immunity, it might also promote tumor growth by stimulating cell proliferation and 
inhibiting cell apoptosis. A high systemic level of IL-10 has been reported for advanced 
colorectal cancer patients (O’Hara et al., 1998; Galizia et al., 2002). Increased level of IL-10 
might better control inflammatory responses and cancer development. Results from our 
study demonstrated a stage dependent association between IL-10 serum level and severity 
of CRC (Stanilov et al., 2010). The highest IL-10 serum level was found in stage-IV CRC 
patients, suggesting a pro-tumorigenic activity of systemic IL-10 in CRC progression and 
play a role in tumor-induced immunosupression in CRC patients. In addition, we 
determined a significantly increased mRNA in tumor tissue compared to normal mucosa 
(Stanilov et al., 2009). Moreover expression of IL-10 mRNA correlated positively with 
increased Foxp3 mRNA expression detected in tumor tissue. These results confirm the role 
of Foxp3 transcription factor in induction of IL-10 production and differentiation of Treg-1 
cells in tumor microenvironment. 
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Cacev et al, 2008 reported a statistically significant decrease in IL-10 mRNA expression in 
tumor tissue then normal mucous depending on IL-10 SNPs. IL-10 promoter genotypes −819 
TT and −592 AA associated with low IL-10 mRNA expression in tumor and corresponding 
normal mucosa. The ‘low-producer genotypes’ were present more frequently in colon 
cancer patients and this difference in genotype distribution was statistically significant. In 
the same study IL-10 -1082AA genotype was associated with lower IL-10 mRNA expression, 
whereas -1082GG genotype was associated with higher IL-10 mRNA expression in tumor 
tissue. In a group of colon cancer patients, an increased frequency of the -1082AA genotype 
compared with control group was observed without statistical significance. The authors 
conclude that IL-10-1082G/A SNP did not influence sporadic colon cancer susceptibility.  
No associations were observed among colorectal cancer patients and controls for IL-10 –
1082G/A and –592C/A genotype frequencies in a case–control study of 62 patients and 124 
matched controls (Crivello et al., 2006). A possible reason for these contradictory results 
might be a small number of patients. 
A recent study of Tsilidis K et al., 2009 investigated the association of 17 candidate SNPs in 
IL-10 with colorectal cancer in 208 patients. The authors established that -1082 promoter 
SNP is implicated. Compared with the AA genotype at the candidate IL10-1082 locus 
(rs1800896), carrying one or two G alleles, a known higher producer of the anti-
inflammatory cytokine IL-10 was associated with lower risk of colorectal cancer (p = 0.03). 
Statistically significant associations with colorectal cancer were observed for three tagSNPs 
in IL10 (rs1800890, rs3024496, rs3024498) and one common haplotype, but these associations 
were due to high linkage disequilibrium with IL10-1082. 
Associations between IL-10 genotypes and cancer chemopreventive strategies and survival 
were also published. Results of Macarthur et al. suggest that IL-10 SNPs may play a role in 
predicting response to chemopreventive strategies. Carriers of the IL-10-592A allele, had a 
statistically significant 50% reduced risk of colorectal cancer when taking regular aspirin, 
whereas risk was not reduced in carriers of the A allele who did not use aspirin, or among 
aspirin users with the CC genotype. It is possible that carriers of the IL-10-592C allele are more 
likely to derive chemopreventive benefits from aspirin in the presence of a lower production of 
their own endogenous anti-inflammatory interleukin-10 (Macarthur et al, 2005).  
In particular proinflammatory genotypes characterized by a low IL-10 producer seem to be 
associated with a worse clinical outcome. Sharma et al. investigated the prognostic value of 
an inflammation-based Glasgow Prognostic Score in advanced colorectal cancer to explore a 
predictive pattern of cytokine gene polymorphisms for clinical outcome (Sharma et al., 
2008). They found that IL-10–592A/C and IL-10 –1082A/G were predictive for overall 
survival. Patients homozygous for IL-10–592 CC had improved overall survival compared 
with those patients with ≥ 1 A allele (median survival, 12.2 ± 0.7 months vs. 8.6 ± 1.6 
months). In contrast, patients homozygous for IL-10–1082 AA had poorer overall survival 
compared with patients with ≥ 1 G allele (median survival, 8.8 months ± 3.2 months vs. 11.2 
± 2.1 months). 
Although the functional effects of polymorphisms in immunosuppressive genes TGFB and 
IL-10 have not yet been elucidated, obviously that they may play a significant role in 
modulating susceptibility, development and survival of colorectal cancer (Fig.1). The 
observation of increased circulating levels of IL-10 in colorectal cancer patients may have 
important implications for future investigations, immunological monitoring and therapeutic 
intervention on neoplastic patients, and suggests a mechanism for tumour cells escaping 
from immune surveillance. 
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Gene/ 
polymorphism 
Genotype or allele associated with 
 Succeptibility -
increased risk of 
CRC 
Protection – 
decreased risk 
of CRC 
Survival rate - 
Shorter 
survival 
References 
PROINFLAMMATORY  
IL-1B -511 C>T  TT ; CT  Ito et al., 2007 
     
TNF-B TNF-B*1/TNF-
B*1 
  Park et al.,1998 
TNF-A 
microsatellite 
a2 allele a5 and a13 allele  Gallager et al., 
1997 ; DeJong et 
al, 2002 
TNF-A- 238 G >A  AA and AG  Jang et al., 2001 
IL6 −174G>C C allele    Landi et al., 2003 
  CC 
 
Chung YC  
et al., 2006 
 GG 
 
 Slattery M  
et al., 2007 
ANTIINFLAMATORY 
TGFB1 -509C>T −509TT   Berndt  
et al., 2007 
TGFB1 Leu10Pro 10Pro/Pro   Berndt  
et al., 2007 
TGFB1 -509C>T  −509TT  Amighofran Z 
et al., 2009 
TGFB1 -509C>T  −509T allele  Chung 
et al., 2007 
TGFB1 -509C>T  −509TT  Fang et al., 2010 
IL-10 -1082 A>G  G allele  Tsilidis K  
et al., 2009 
IL-10 -592 C> A −592 AA   Cacev et al, 2008 
IL-10 -819 C>T −819 TT   Cacev et al, 2008 
IL-10 -1082 A>G ; 
-592 C> A 
  IL-10–1082AA 
IL-10–592 AA 
Sharma  
et al., 2008 
Table 1. Involvement of IL-1; TNF, IL-6, IL-10 and TGF- gene polymorphisms into 
colorectal cancer.  
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4. Role of IL-12-related cytokines  
Human interleukin (IL)-12 (IL-12p70) is a disulfide-linked heterodimer composed of two 
subunits p40 and p35. IL-12p40 subunit can be secreted as monomer, which can also form 
IL-23, a heterodimeric pro-inflammatory cytokine composed of p40 and p19 subunits, and a 
homodimer, IL-12p80, which can act as an IL-12 and IL-23 antagonist by competing at their 
receptors (Hoelscher, 2004). The IL-12 family cytokines are produced by antigen-presenting 
cells such as macrophages and dendritic cells and play critical roles in the regulation of Th 
cell differentiation. IL-12 induces IFN-Ǆ production by NK and T cells and differentiation to 
Th1 cells. IL-23 induces IL-17 production by memory T cells and expands and maintains 
inflammatory Th17 cells. IL-27 induces the early Th1 differentiation and generation of IL-10-
producing regulatory T cells. Although IL-12p70 is one of the most powerful antitumor 
cytokine (Colombo and Trinchieri, 2002), accumulating evidence revealed that the 
individual members of the IL-12 family play distinct roles in the regulation of antitumor 
immune responses. 
Several polymorphisms have been described in the IL12B gene, encoding IL-12p40 subunit, 
including a single-nucleotide polymorphism in 3’-untranslated region (UTR) of IL12B with 
number rs3212227 and a complex polymorphism in promoter region of the IL12B 
(IL12Bpro), resulting from 4bp microinsertion combined with an AA/GC transition 
(rs17860508). Moreover, several studies have demonstrated that these two polymorphisms 
affect gene expression and IL-12 production (Morahan et al., 2001; Seegers et al., 2002; 
Muller-Berghaus et al., 2004; Stanilova and Miteva, 2005; Stanilova et al., 2008; Dobreva et 
al., 2009) and consequently could influence the pathogenesis of CRC. To test this hypothesis, 
we performed a case-control study to investigate the association between these gene 
polymorphisms and the risk of colorectal cancer. The paper of Miteva et al., 2009 was the 
first study which investigated the distribution of IL12Bpro polymorphism and the 
+16974A/C SNP in 3’UTR of IL12B among 85 Bulgarian patients with colorectal cancer. No 
differences in genotype and allelic frequencies of the IL12B polymorphisms in the promoter 
and 3’UTR regions between patients with CRC and controls were found, either when 
patients were analyzed as a whole group or when they were separated according to the 
TNM classification or clinical characteristics such as tumor location, differentiation degree, 
lymph node and metastases status. These data are in principal agreement with other studies, 
where no association with SNP in 3’UTR of IL12B was found in pathogenesis of other 
related gastrointestinal diseases. Navaglia et al. have reported that none of the studied IL12B 
gene polymorphisms, including SNP in 3’UTR, was correlated with Helicobacter pylori 
infection and intestinal metaplasia (Navaglia et al., 2005). There was no statistically 
significant association between the SNPs investigated in IL-12A gene ((+7506 A>T, +8707 
A>G, +9177 T>A, +9508 G>A) and colorectal cancer risk in the study of Landi et al., 2006. 
The lack of association suggests that the role of both investigated polymorphisms in IL12B 
in susceptibility of sporadic colorectal cancer can be excluded. However, these findings do 
not exclude a key role for IL-12p40 in development and progression of the CRC. In our 
investigations, we have demonstrated that serum levels for IL-12p40 and IL-23 were 
significantly higher in patients compared to healthy donors. Additionally, we found the 
highest level of IL-12p40 in sera from patients with I stage of CRC and significantly lower in 
patients with more advanced stages. (Miteva et al., 2009; Stanilov et al., 2009; Stanilov et al., 
2010). In respect to recent findings regarding different proteins in IL-12 related family which 
share the p40 subunit, we could attribute the relationship of decreased serum level of IL-
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12p40 and severity of CRC to the action of Th1-promoting form of IL-12, such as IL-12p70, 
or free IL-12p40 in monomeric and homodimeric form.  
In a recent study there were significant differences in the genotype and allele frequencies of 
the IL-12 gene 16974 A/C polymorphism between the group of patients with glioma and the 
control group (Zhao et al., 2009). Moreover, genotypes carrying the IL-12 16974 C variant 
allele were associated with decreased serum IL-12p40 and IL-27p28 levels compared to the 
homozygous wild-type genotype in patients with glioma. 
The promoter polymorphisms in the human IL12B gene could influence JNK and p38 
MAPKs control of IL-12p40 expression in human PBMC in response to mitogens and 
proinflammatory stimuli. The study of Dobreva et al., revealed that JNK and p38 MAPK 
inhibition in PBMC stimulated with C3bgp and LPS, significantly upregulated the IL-12p40 
production from IL12Bpro-1 homozygotes and did not influence the IL-12p40 production 
from 1.2/2.2 genotypes (Dobreva et al., 2009). Also, the p38 inhibition led to significant 
increase of IL-12p40 production in IL12Bpro-1 homozygous PBMC stimulated with PHA. 
IL-12p40 is secreted at a 50-fold excess compared with IL-12p70 in a murine shock model 
(Wysocka et al., 1995) and at a 10-20-fold excess by stimulated human peripheral blood 
mononuclear cells (D’Andrea et al., 1992). IL-12p40 chain may form also a homodimer IL-
12p80 that serves as an IL-12p70 and IL-23 antagonist by competing for binding at the 
receptor complexes of both cytokines (Cooper & Khader, 2006). The proper balance between 
IL-12p40-related cytokines play a key immunoregulatory role and control the appearance of 
protective Th1-mediated immune response. Current results demonstrated an opposite effect 
of JNK and p38 MAPKs inhibition on the IL-12p70 and IL-23 production in LPS and C3bgp-
stimulated PBMC (Dobreva et al., 2008).Our results demonstrated that p38 MAPK inhibition 
down regulates IL-23 and up regulates IL-12p40/p70 inducible expression suggesting the 
benefit of p38 control in the treatment of inflammatory conditions. 
IL-12 related cytokines (IL-12p70; IL-12p40 and IL-23) produced locally or systemic exhibit a 
significant role in progression of CRC. Accumulating evidence revealed that the individual 
members of the IL-12 family play distinct roles in progression of CRC. Studies have defined 
IL-12p70 as an important factor for the differentiation of naive T cells into IFN-Ǆ producing 
Th1 cells and exhibits anti-tumor activity (Brunda et al., 1995; Gri et al., 2002). Although the 
antitumor activities of IL-12p70 are well characterized, studies of the role of IL-23 in 
development of CRC in humans are contradictory. Some authors reported that IL-23, as well 
as IL-12p70, have anti-tumor activity in murine tumor models (Wang et al., 2003; Lo et al., 
2003; Shan et al.,2006). Contradictory results have been reported in studies of Langowski et 
al., 2006 which showed data that IL-23 promotes tumor incidence and growth in various 
human cancers. In this respect our results for enhanced serum levels of IL-23 in cancer 
patients regardless of severity supported the hypothesis that IL-23 promotes tumor 
development unlike IL-12p70 (Stanilov et al., 2010). Besides, the highest increase in 
transcriptional activity in tumor samples for IL-23p19 mRNA has been also reported in our 
study (Stanilov et al., 2009). IL-23p19 mRNA was approximately 29 fold upregulated 
(p=0.0009), whereas IL-12p35 mRNA was not significantly upregulated, when compared to 
their adjacent normal tissue. This difference indicated that IL-23 could be synthesized many 
times more than IL-12p70 in tumor tissue. Based on our and others data, we could assume 
that increased serum and locally produced IL-23 indicates impaired anti-tumor immune 
response and could be associated with poor prognosis of CRC. A molecular mechanism 
involved in IL-23 activities includes STAT3 activation. STAT3 signaling within the tumor 
microenvironment was recently elucidated to induce a protumor cytokine, IL-17 and IL-22, 
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while inhibiting a central antitumor cytokine, IL-12p70, thereby shifting the balance of 
tumor immunity toward tumorigenesis. Interestingly, unlike spleen Treg cells, tumor-
associated Treg cells express IL-23R and activate STAT3 in response to IL-23, leading to 
upregulation of the Treg-specific transcription factor Foxp3 and the immunosuppressive 
cytokine IL-10 (Xu M et al., 2010). Collectively, IL-12 and IL-23 play critical roles in the 
regulation of antitumor or protumor response in respective situation. 
5. Conclusion 
In recent years, efforts have been made to identify genes involved in the genetic 
predisposition or progression of colorectal cancer. During the last two decades, many of the 
‘candidate’ cytokine genes implicated in colorectal tumorigenesis have been identified and 
were summarized in this review. As cancer is a complex genetic disease, it is probable that 
besides oncogenes and tumor suppressor genes a number of cytokine genes also contribute 
to cancer susceptibility and development. Moreover cytokines are a key-player in 
inflammation, which have protumoral effect and mediated anti-tumor immune response. 
Cytokines present in tumor microenvironment have gained much attention due to their 
influence on cell activation, growth, differentiation or cell migration and they are 
increasingly recognized as potential cancer modifying genes. While numerous factors 
influence the inflammatory response in cancer, the role of an individual’s genetic 
background has recently received increasing attention.  
Cytokines and their receptors are often encoded by highly polymorphic genes. Single-
nucleotide polymorphisms in cytokine genes potentially affect their production by either 
creating or eliminating key binding motifs within promoter and other regulatory sequences. 
In investigating disease–gene associations, there is a strong argument for focusing on 
polymorphisms of functional significance. Up to date contradictory results from case-control 
study have been published concerning cytokine gene polymorphisms and colorectal cancer 
development. Obviously reasons for such results included different numbers of patients; 
their ethnicity and differences in clinical and pathological data. In any case-control study, 
there are potential limitations. Despite the limitations of most published studies, the 
preliminary literature indicates that selected cytokine polymorphisms, particularly in IL-10; 
TGF-; IL-6 and TNF- are required in colorectal cancer. Data included in this review 
summarized in table1 suggest that functional cytokine polymorphisms participate more in 
the onset of colorectal cancer progression rather than in its initial development. Due to the 
strong evidence concerning the biological significance of these SNPs further studies and 
meta analysis are needed to evaluate the significance in the clinic. Careful selection of SNPs 
to cover the whole length of a candidate gene sequence so that areas of association can be 
defined and informative haplotypes constructed. Emerging genotyping technologies will 
facilitate such definitive, comprehensive studies.  
The preliminary data indicate that larger studies are required to confirm or reject existing 
results, extend studies to include more detailed genotype and haplotype analysis, and 
combine genotype and gene expression studies in the same subjects. Even larger numbers of 
cases and controls would be required to demonstrate more modest odds ratios with higher 
statistical power. Collection of definitive clinical and pathological data for all cases must be 
an integral part of such an approach. 
Such studies will contribute significantly to our understanding of the biological role of 
cytokine polymorphisms in colorectal cancer development.  
www.intechopen.com
 
Colorectal Cancer Biology – From Genes to Tumor 
 
72
6. References 
Abraham LJ, & Kroeger KM. (1999) Impact of the −308 TNF promoter polymorphism on the 
transcriptional regulation of the TNF gene: relevance to disease. J Leukoc Biol, 
66:pp562–566. 
Amirghofran Z., Jalali SA, Ghaderi A, & Hosseini SV. (2009) Genetic polymorphism in the 
transforming growth factor 1 gene (-509 C/T and -800G/A) and colorectal cancer. 
Cancer genetics and cytogenetics, 190:pp21-25 
Belluco C, Olivieri F, Bonafe M, Giovagnetti S, Mammano E, Scalerta R, Ambrosi A, 
Franceschi C, Nitti D, & Lise M. (2003) −174 G>C polymorphism of interleukin 6 
gene promoter affects interleukin 6 serum level in patients with colorectal cancer. 
Clin Cancer Res; 9:pp2173–2176. 
Berndt S, Huang WY, Chatterjee N, Yeager M, Welch R, Chanock S, Weissfeld J, Schoen R &. 
Hayes R. (2007) Transforming growth factor beta 1 (TGFB1) gene polymorphisms 
and risk of advanced colorectal adenoma, Carcinogenesis, 28 pp.1965–1970,  
Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF, Oksenberg J, 
McNicholl J, Pociot F, Hardt C & D’Alfonso S. (1999) Cytokine gene polymorphism 
in human disease: on-line databases. Genes and immunity 1:3-19 
Bonafe M., Olivieri F., & Cavallone L., Giovagnetti S., Marchegiani F., Cardelli M., Pieri C., 
Marra M., Antonicelli R., Lisa R., Rizzo M. R., Paolisso G., Monti D., Franceschi C. 
(2001) A. gender-dependent genetic predisposition to produce high levels of IL-6 is 
detrimental for longevity. Eur. J. Immunol., 31: pp2357-2361. 
Brunda MJ, Luistro L, Hendrzak JA, Fountoulakis M, Garotta G, & Gately MK (1995) Role of 
interferon-Ǆ in mediating the antitumor efficacy of interleukin-12. J Immunother, 17: 
pp71-77.  
Cacev T, Jokić M, Loncar B, Krizanac S, & Kapitanović S. (2010) Interleukin-6-174 G/C 
polymorphism is not associated with IL-6 expression and susceptibility to sporadic 
colon cancer. DNA Cell Biol.; 29(4):177-82. 
Cacev T, Radosevic S, Krizanac S, & Kapitanovic S. (2008) Influence of interleukin-8 and 
interleukin-10 on sporadic colon cancer development and progression. 
Carcinogenesis; 29:pp1572-1580 
Chung Y.C. & Y.F. Chang, (2003), Serum interleukin-6 levels reflect the disease status of 
colorectal cancer, J. Surg. Oncol. 83: pp. 222–226. 
Chung YC., Chaen YL & Hsu CP. (2006) Clinical significance of tissue expression of 
interleukin-6 in colorectal carcinoma. Anticancer Res. 26:pp3905-3911. 
Chung SJ, Kim JS, Jung HC, & Song IS. (2007) Transforming growth factor-ǃ1 509T reduces 
risk of colorectal cancer, but not adenoma in Koreans. Cancer Sci. 98:pp401–404 
Colombo M. P. & G. Trinchieri. (2002) Interleukin-12 in anti-tumor immunity and 
immunotherapy. Cytokine and growth factor Reviews, 13: pp155-168,  
Cooper, A.M. & Khader, S.A. (2006) IL-12p40: an inherently agonistic cytokine. Trends 
Immunol. 28, pp33-38. 
Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, Baus D, Kaufmann R, 
Huber LA, Zatloukal K, Beug H, Ohlschläger P, Schütz A, Halbhuber KJ, & 
Friedrich K. (2005) Persistent STAT3 activation in colon cancer is associated with 
enhanced cell proliferation and tumor growth. Neoplasia. 7:pp545-55. 
Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, & Woo P. (1999) Polymorphic 
haplotypes of the interleukin-10 5’flanking region determine variable interleukin-10 
www.intechopen.com
 
Cytokine Gene Polymorphisms in Colorectal Cancer 
 
73 
transcription and are associated with particular phenotypes of juvenile rheumatoid 
arthritis. Arthritis Rheum; 42, pp1101-1108. 
Crivello A, Giacalone A, Vaglica M, Scola L, Forte GI, Macaluso MC, Raimondi C, Di Noto 
L, Bongiovanni A, Accardo A, Candore G, Palmeri L, Verna R, Caruso C, Lio D, & 
Palmeri S. (2006) Regulatory cytokine gene polymorphisms and risk of colorectal 
carcinoma. Ann N Y Acad Sci., 1089:pp98–103 
D’Andrea, A., Rengaraju, M., Valiante, N.M., Chehimi, J., Kubin, M., Aste, M., Chan, S.H., 
Kobayashi, M., Young, D., Nickbarg, E., Chizzonite, R., Wolf, S.F., & Trinchieri, G. 
(1992) Production of natural killer cell stimulatory factor (NKSF/IL-12) by 
peripheral blood mononuclear cells. J. Exp. Med. 176,pp 1387-1398. 
D'Alfonso S, Rampi M, Rolando V, Giordano M, & Momigliano-Richiardi P (2000) New 
polymorphisms in the IL-10 promoter region. Genes Immun 1:pp231-233. 
De Jong MM, Nolte IM, te Meerman GJ, van der Graaf WT, de Vries EG, Sijmons RH, 
Hofstra RM, & Kleibeuker JH. (2002) Low-penetrance genes and their involvement 
in colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev 11:pp1332-1352 
Dobreva Z. Stanilova S. & Miteva L. (2008) Differences in the inducible gene expression and 
protein production of IL-12p40, Il-12p70 and IL-23: involvement of p38 and JNK 
kinase pathways. Cytokine, 43:pp76-82  
Dobreva Z., Stanilova S, & Miteva L. (2009) Influence of JNK and p38 MAPKs inhibition on 
IL-12p40 and IL-23 production depending on IL12B promoter polymorphism. Cell 
Mol Biol Lett, , 14: pp609-621 
Dranoff G (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer, 4: 
pp11-22. 
Duch CR, Figueiredo MS, Ribas C, Almeida MS, Colleoni GW, & Bordin JO. (2007) Analysis 
of polymorphism at site −174 G/C of interleukin-6 promoter region in multiple 
myeloma. Braz J Med Biol Res. 40:pp265-267. 
Elliott RL, Blobe GC. (2005) Role of transforming growth factor h in human cancer. J Clin 
Oncol; 23: pp2078–93. 
El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, 
Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF Jr, & Rabkin 
CS. (2000) Interleukin-1 polymorphisms associated with increased risk of gastric 
cancer. Nature 404: pp398-402,  
El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, Stanford JL, 
Mayne ST, Goedert J, Blot WJ, Fraumeni JF Jr, & Chow WH. (2003) Increased risk of 
noncardia gastric cancer associated with proinflammatory cytokine gene 
polymorphisms. Gastroenterology; 124: pp1193–1201. 
Esfandi F, Mohammadzadeh Ghobadloo S, & Basati G. (2006) Interleukin-6 level in patients 
with colorectal cancer. Cancer Lett. 244: pp76-78 
Eskdale J & Galager G (1995) A polymorphic dinucleotide repeat in the human IL- 10 
promoter region. Immunogenetics 42: pp444-445. 
Eskdale J, Kube D, Tesch H, & Gallagher G (1997) Mapping of the human IL10 gene and 
further characterization of the 5' flanking sequence. Immunogenetics 46:pp120-128 
European Bioinformatics Institute, Sanger Institute. SNP database: Ensembl Genome 
Browser. 2006. Available at: http://www.ensembl.org/index.html. 
Fang F, Yu L, Zhong Y, & Yao L. (2010) TGFB1 509 C/T polymorphism and colorectal cancer 
risk: a meta-analysis. Med Oncol. Dec; 27: pp1324-1328.  
www.intechopen.com
 
Colorectal Cancer Biology – From Genes to Tumor 
 
74
Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, & Woo P. (1998) 
The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 
transcription and plasma IL-6 levels, and an association with systemic-onset 
juvenile chronic arthritis. J Clin Invest.; 102:pp1369-1376 
Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S, & Cohen A. (1995) High levels of 
transforming growth factor ǃ1 correlate with disease progression in human colon 
cancer. Cancer Epidemiol Biomarkers Prev, 4:pp549–554 
Galizia G, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L, Imperatore V, Catalano 
G, Pignatelli C, & De Vita F. (2002) Prognostic significance of circulating IL-10 and 
IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol, 102: 
pp169–178,. 
Gallagher, G., Lindemann, M., Oh, H. H., Ferencik, S., Walz, M. K.,Schmitz, A., Richards, S., 
Eskdale, J., Field, M., & Grosse-Wilde, H. (1997) Association of the TNFa2 
microsatellite allele with the presence of colorectal cancer. Tissue Antigens, 50: 
pp47–51,. 
Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, (1999) Genetic 
control of the circulating concentration of transforming growth factor type ǃ1. Hum 
Mol Genet.; 8:pp93–97 
Gri G, Chiodoni C, Gallo E, Stoppacciaro A, Liew F, & Colombo M (2002) Antitumor effect 
of Interleukin (IL)-12 in the absence of endogeneous IFN-Ǆ: a role for intrinsic 
tumor immunogenicity and IL-15. Cancer Res, 62: pp4390-4397. 
GunterM, Canzian F, Landi S, Chanock S, Sinha R, & Rothman N. (2006) Inflammation-
Related Gene Polymorphisms and Colorectal Adenoma. Cancer Epidemiol Biomarkers 
Prev, 15: pp1126-1131  
Hoelscher, C. (2004) The power of combinatorial immunology: IL-12 and IL-12-related 
dimeric cytokines in infectious diseases. Med Microbiol Immunol., 193, pp1-17.  
Hollegaard MV & Bidwell JL, (2006) Cytokine gene polymorphism in human disease: on-
line databases, Supplement 3. Genes Immun., 7:pp269-76.  
Howell,W.M & Matthew J. Rose-Zerilli. (2007) Cytokine gene polymorphisms, cancer 
susceptibility, and prognosis. J. Nutr., 137, pp194–199. 
Huang 5., DeGuzman A., Bucana C. D., & Fidler I. J. (2000) Nuclear factor-kB activity 
correlates with growth, angiogenesis, and metastasis of human melanoma cells in 
nude mice. Clin. Cancer. Res., 6: pp2573-2578. 
Hussain SP, Harris CC, Inflammation and cancer: an ancient link with novel potentials. Int. 
J. Cancer 2007;121:pp2373-2380. 
Hwang IR, Kodama T, Kikuchi S, Sakai K, Peterson LE, Graham DY, &Yamaoka Y. (2002) 
Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1ǃ production 
in Helicobacter pylori infection. Gastroenterology; 123:pp1793–803. 
Ito H, Kaneko K, Makino R, Konishi K, Kurahashi T, Yamamoto T, Katagiri A, Kumekawa 
Y, Kubota Y, Muramoto T, Mitamura K, & Imawari M (2007) Interleukin-1beta gene 
in esophageal, gastric and colorectal carcinomas. Oncol Rep. 18:pp473-81. 
Jang WH, Yang YI, Yea SS et al (2001) The −238 tumor necrosis factor-alpha promoter 
polymorphism is associated with decreased susceptibility to cancers. Cancer Lett 
166:pp41–46 
Jobin C & Sartor B, (2000) The IκB/NF-κB system: a key determinant of mucosal 
inflammation and protection. Am J Physiol Cell Physiol, 278 ppC451-C462  
www.intechopen.com
 
Cytokine Gene Polymorphisms in Colorectal Cancer 
 
75 
Landi S, Gemignani F., Bottari F., Gioia-Patricola L, Guino E, Cambray M, Biondo S, Capella 
G, Boldrini L, Canzian F & Moreno V. (2006) Polymorphisms within inflammatory 
genes and colorectal cancer. Journal of Negative Results in BioMedicine, 5:pp5-15  
Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G, & Canzian 
F; Bellvitge Colorectal Cancer Study Group (2003). Association of common 
polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor 
alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with 
colorectal cancer. Cancer Res, 63:pp3560–3566. 
Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, 
Kastelein RA, & Oft M (2006) IL-23 promotes tumor incidence and growth. Nature, 
442: pp461-465.  
Lin W, & Karin M (2007) A cytokine-mediated link between innate immunity, inflammation 
and cancer. J Clin Invest, 117: pp1175-1183.  
Lo CH, Lee SC, Wu PY, Pan WY, Su J, Cheng CW, Roffler SR, Chiang BL, Lee CN, Wu CW, 
& Tao MH (2003) Antitumor and antimetastatic activity of IL-23. J Immunol, 171: 
pp600-607.  
Macarthur M., Georgina L. Hold, & Emad M. El-Omar (2004) Inflammation and Cancer II. 
Role of chronic inflammation and cytokine gene polymorphisms in the 
pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 
286: ppG515–G520 
Macarthur M, Sharp L, Hold GL, Little J, & El-Omar EM. (2005) The role of cytokine gene 
polymorphisms in colorectal cancer and their interaction with aspirin use in 
northeast of Scotland. Cancer Epidemiol Biomarkers Prev.;14:pp1623–1628. 
Miteva L, Stanilov N, Deliysky T, Mintchev N, & Stanilova S. (2009) Association of 
polymorphisms in regulatory regions of interleukin-12p40 gene and cytokine 
serum level with colorectal cancer. Cancer Investigation, , 27:pp924-931 
Mocellin S, Maricola FM, & Young HA: (2004) Interleukin-10 and the immune response 
against cancer: a counterpoint. J Leukoc Biol, 78: pp1043-1051. 
Mocellin S, Panelli MC, Wang E, Nagorsen D, & Marincola FM (2003) The dual role of IL-10. 
Trends Immunol, 24: pp36-43. 
Moore KW, de Waal MR, Coffman RL, & O'Garra A. (2001) Interleukin-10 and the 
interleukin-10 receptor. Annu Rev Immunol, 19:pp683–765. 
Morahan, G.; Huang, D.; Wu, M.; Holt, B.J.; White, G.P.; Kendall, G.E.; Sly, P.D.; Holt, P.G. 
(2002) Association of IL12B promoter polymorphism with severity of atopic and 
non-atopic asthma in children. Lancet., 360, pp455–459. 
Morahan, G.; Huang, D.; Ymer, S.I.; Cancilla, M.R.; Stephen, K.; Dabadghao, P.; Werther, G.; 
Tait, B.D.; Harrison, L.C.; & Colman, P.G. (2001) Linkage disequilibrium of a type 1 
diabetes susceptibility locus with a regulatory IL12B allele. Nat Genet., 27, pp218-
221. 
Moustakas A, Pardali K, Gaal A, & Heldin CH. (2002) Mechanisms of TGF-ǃ signaling in 
regulation of cell growth and differentiation. Immunol Lett, 82:pp85–91 
Muller-Berghaus, J.; Kern, K.; Paschen, A.; Nguyen, X.D.; Klüter, H.; Morahan, G. & 
Schadendorf, D. (2004) Deficient IL-12p70 secretion by dendritic cells based on 
IL12B promoter genotype. Genes Immun., 5, pp 431-434. 
www.intechopen.com
 
Colorectal Cancer Biology – From Genes to Tumor 
 
76
Nakagoe T., Tsuji T., Sawai T., Tanaka K., Hidaka S. & S. Shibasaki. (2003) Increased serum 
levels of interleukin-6 in malnourished patients with colorectal cancer, Cancer Lett. 
202: pp. 109–115. 
Navaglia, F.; Basso, D.; Zambon, C.F.; Ponzano, E.; Caenazzo, L.; Gallo, N.; Falda, A.; 
Belluco, C.; Fogar, P.; Greco, E.; Di Mario, F.; Rugge, M.; & Plebani, M. (2005) 
Interleukin 12 gene polymorphisms enhance gastric cancer risk in H pylori infected 
individuals. J Med Genet., 42, pp 503-510. 
Nusrat A., Sitaraman S. V., & Neish A. (2001) Interaction of bacteria and bacterial toxins 
with intestinal epithelial cells. Curr. Gastroenterol. Rep., 3: pp392-398. 
O’Hara RJ, Greenman J, MacDonald AW, Gaskell KM, Topping KP, Duthie GS, Kerin MJ, 
Lee PW, & Monson JR (1998) Advanced colorectal cancer is associated with 
impared interleukin 12 and enhanced interleukin 10 production. Clin Cancer Res, 4: 
pp1943-1948,. 
Park KS, Mok JW, Rho SA & Kim JC (1998) Analysis of TNFB and TNFA Ncol RFLP in 
colorectal cancer. Mol Cells 8:pp246–249 
Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2:533–543 
Pociot, F., Briant, L., Jongeneel, C. V., Molvig, J., Worsaae, H., Abbal, M., Thomsen, M., 
Nerup, J., & Cambon-Thomsen, A. (1993) Association of tumor necrosis factor 
(TNF) and class II major histocompatibility complex alleles with the secretion of 
TNF- and TNF- by human mononuclear cells: a possible link to insulin-
dependent diabetes mellitus. Eur. J. Immunol., 23: pp224–231. 
Schulte CM, Goebell H, & Roher HD (2001) C-509T polymorphism in the TGF-ǃ1 gene 
promoter: impact on Crohn’s disease susceptibility and clinical course? 
Immunogenetics 53:pp178–182 
Schuster N, & Krieglstein K. (2002) Mechanisms of TGF-hmediated apoptosis. Cell Tissue 
Res; 307:pp1–14. 
Seegers, D.; Zwiers, A.; Strober, W.; Pena, A.S.; & Bouma, G. (2002) A TaqI polymorphism in 
the 3’ UTR of the IL-12 p40 gene correlates with increased IL-12 secretion. Genes 
Immun., 3, pp 419-423. 
Shan B, Hao J, & Li Q, & Tagawa M (2006) Antitumor activity and immune enhancement of 
murine interleukin-23 expressed in murine colon carcinoma cells. Cell Mol Immunol, 
3: pp47-52. 
Sharma R, Zucknick M, London R, Kacevska M, Liddle C, & Clarke SJ. (2008) Systemic 
inflammatory response predicts prognosis in patients with advanced-stage 
colorectal cancer. Clin Colorectal Cancer., 7:pp331–337 
Slattery ML, Wolff RK, Herrick JS, Caan BJ, & Potter JD (2007) IL6 genotypes and colon and 
rectal cancer. Cancer Causes Control.; 18:pp1095-1105. 
Stanilov N, Miteva L, Mintchev N, & Stanilova S. (2009) High expression of Foxp3, IL-23p19 
and surviving mRNA in colorectal carcinoma. International Journal of Colorectal 
Disease, 24: pp151-157. 
Stanilov N., Miteva L, Deliyski T, Jovchev J, & Stanilova S. (2010) Advanced colorectal 
cancer is assosiated with enhanced Interleukin-23 and Interleukin -10 serum level. 
LabMedicine, 41 :pp 159-163 
Stanilova, S. & Miteva, L. (2005) Taq-I polymorphism in 3’UTR of the IL-12 and association 
with IL-12p40 production from human PBMC. Genes Immun., 6, pp364-366. 
www.intechopen.com
 
Cytokine Gene Polymorphisms in Colorectal Cancer 
 
77 
Stanilova, S.; Miteva, L.; & Prakova, G. (2008) IL-12Bpro and GSTP1 polymorphisms in 
association with silicosis. Tissue Antigens., 71, pp 169-174. 
Steven H. Itzkowitz & Xianyang Yio. (2004) Inflammation and Cancer IV. Colorectal cancer 
in inflammatory bowel disease: the role of inflammation . Am J Physiol Gastrointest 
Liver Physiol 287: ppG7–G17. 
Su JL, Lai KP, Chen CA, Yang CY, Chen PS, Chang C, Chou CH, Hu CL, Kuo ML, Hsieh CY 
& Wei LH (2005) A novel peptide specifically binding to interleukin-6 receptor (gp 
80) inhibits angiogenesis and tumor growth. Cancer Res, 65: pp 4827-4835. 
Sugimoto M, Furuta T, Shira N, Nakamura A, Kajimura M, Sugimura H, & Hishida A. 
(2007) Effects of interleukin-10 gene polymorphism on the development of gastric 
cancer and peptic ulcer in Japanese subjects. Journal of Gastroenterology and 
Hepatology., 22: pp1443-1449. 
Swantek JL, Cobb MH, & Gepperd DT. (1997) Jun N-Terminal Kinase/Stress – Activated 
Protein Kinase (JNK/SAPK) Is Required for Lipopolysaccharide Stimulation of 
Tumor necrosis factor alpha (TNF-) Translation: Glucocorticoids Inhibit TNF- 
Translation by blocking JNK/SAPK. Mol Cell Biol.; 17: pp6274-6282. 
Sweet MJ, & Hume DA. (1996) Endotoxin signal transduction in macrophages. J. Leukoc. 
Biol.; 60:8-26. 
Terry C. F., Loukaci V., & Green F. R. (2000) Cooperative influence of genetic 
polymorphisms on interleukin 6 transcriptional regulation. J. Biol. Chem., 275: 
pp18138-18144. 
Theodoropoulos G, Papaconstantinou I, Felekouras E, Nikiteas N, Karakitsos P, 
Panoussopoulos D, Ch Lazaris A, Patsouris E, Bramis J, & Gazouli M. (2006) 
Relation between common polymorphisms in genes related to inflammatory 
response and colorectal cancer. World J Gastroenterol; 12: pp5037-5043 
Tsilidis KK, Helzlsouer KJ, Smith MW, Grinberg V, Hoffman-Bolton J, Clipp SL, 
Visvanathan K, & Platz EA. (2009) Association of common polymorphisms in IL10, 
and in other genes related to inflammatory response and obesity with colorectal 
cancer. Cancer Causes Control. 20:pp1739-51. 
Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, & Hutchinson IV. (1997) An 
investigation of polymorphism in the interleukin-10 gene promoter. Eur J 
Immunogenetics; 24:pp1-8. 
Wang YQ, Ugai S, Shimozato O, Yu L, Kawamura K, Yamamoto H, Yamaguchi T, Saisho H, 
& Tagawa M (2003) Induction of systemic immunity by expression of interleukin-
23 in murine colon carcinoma cells. Int J Cancer, 105: pp820-824.  
Watanabe Y, Kinoshita A, Yamada T, Ohta T, Kishino T, Matsumoto N, Ishikawa M, 
Niikawa N, & Yoshiura K. (2002) A catalog of 106 single nucleotide polymorphisms 
(SNPs) and 11 other types of variations in genes for transforming growth factor- 1 
(TGF- 1) and its signaling pathway. J Hum Genet 47:pp 478-483. 
Waterston A, & Bower M. (2004) TNF and cancer: good or bad? Cancer therapy; 2: pp131-148.  
Wilkening S, Tavelin B, Canzian F, Enquist K, Palmqvist R, Altieri A, Hallmans G, 
Hemminki K, Lenner P, & Försti A. (2008) Interleukin promoter polymorphisms 
and prognosis in colorectal cancer. Carcinogenesis; 29:pp1202–6. 
Wong SF,& Lai LC. (2001) The role of TGFǃ in human cancers. Pathology; 33:85–92 
www.intechopen.com
 
Colorectal Cancer Biology – From Genes to Tumor 
 
78
Wysocka, M., Kubin, M., Vieira, L.Q., Ozmen, L., Garotta, G., Scott, P. & Trinchieri, G. (1995) 
Interleukin 12 is required for interferon-Ǆ production and lethality in 
lipopolysaccharide-induced shock in mice. Eur. J. Immunol. 25,pp 672-676 
Xu M, Mizoguchi I, Morishima N, Chiba Y, Mizuguchi J, & Yoshimoto T, Regulation of 
Antitumor Immune Responses by the IL-12 Family Cytokines, IL-12, IL-23, and IL-
27. (2010) Clinical and Developmental Immunology. Volume 2010, Article ID 832454, 
doi:10.1155/2010/832454 
Xu Y, & Pasche B. (2007) TGF-ǃ signaling alterations and susceptibility to colorectal cancer. 
Hum Mol Genet, 15:ppR14–R2016  
Yao, J.; Mackman, N.; Edgington, T. S., & Fan, S. T. (1997) Lipopolysaccharide induction of 
the tumor necrosis factor - alpha promoter in human monocytic cells. Regulation 
by Egr-1, c-Jun and NF-kappa B transcription factors. J. Biol. Chem., 272: pp17795-
17801. 
Yu H. & R. Jove. The stats of cancer—new molecular targets come of age, (2004) Nature 
Reviews Cancer, vol. 4, pp. 97–105. 
 Zhao B, Meng LQ, Huang HN, Pan Y & Xu Q. A (2009) Novel Functional Polymorphism, 
16974 A/C, in the Interleukin-12-3′ Untranslated Region Is Associated with Risk of 
Glioma. DNA and Cell Biology. 28: pp335-341. 
www.intechopen.com
Colorectal Cancer Biology - From Genes to Tumor
Edited by Dr. Rajunor Ettarh
ISBN 978-953-51-0062-1
Hard cover, 446 pages
Publisher InTech
Published online 10, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Colorectal cancer is a common disease, affecting millions worldwide and represents a global health problem.
Effective therapeutic solutions and control measures for the disease will come from the collective research
efforts of clinicians and scientists worldwide. This book presents the current status of the strides being made to
understand the fundamental scientific basis of colorectal cancer. It provides contributions from scientists,
clinicians and investigators from 20 different countries. The four sections of this volume examine the evidence
and data in relation to genes and various polymorphisms, tumor microenvironment and infections associated
with colorectal cancer. An increasingly better appreciation of the complex inter-connected basic biology of
colorectal cancer will translate into effective measures for management and treatment of the disease.
Research scientists and investigators as well as clinicians searching for a good understanding of the disease
will find this book useful.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Spaska Stanilova (2012). Cytokine Gene Polymorphisms in Colorectal Cancer, Colorectal Cancer Biology -
From Genes to Tumor, Dr. Rajunor Ettarh (Ed.), ISBN: 978-953-51-0062-1, InTech, Available from:
http://www.intechopen.com/books/colorectal-cancer-biology-from-genes-to-tumor/cytokine-gene-
polymorphisms-in-colorectal-cancer
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
